Drug Profile
Research programme: antiallergics - Xerion
Alternative Names: Antiallergics research programme - XerionLatest Information Update: 08 May 2008
Price :
$50
*
At a glance
- Originator Xerion Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma; Hypersensitivity
Most Recent Events
- 01 Mar 2004 Preclinical trials in Allergic asthma in Germany (Parenteral)
- 01 Mar 2004 Preclinical trials in Allergy in Germany (Parenteral)